MAP2K7 and acute lymphoblastic leukemia: Indeed, a clinical trial for relapsed/refractory ALL combining standard VXLD induction with pevonedistat is currently under development, and a subsequent trial could explore the combination of pevonedistat plus agents that inhibit the MEK/ERK pathway.